350TiP A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2− breast cancer (CAPItello-291)N. Turner, S. Howell,K. Jhaveri,H. Gomez, M. Toi, X. Hu,S. Loibl,H.S. Rugo, P. Ni,E. De Bruin, C.M.A.A. Orbegoso, G. Schiavon, A. Foxley,M. OliveiraAnnals of Oncology（2020）引用 9|浏览3暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
